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Abstract
A method of decreasing plasma cholesterol is disclosed. The method includes oral administration of
coprostanol-producing bacteria to humans. These organisms, once in the small intestine, will reduce free
cholesterol to coprostanol, which is absorbed poorly. Pharmaceutical compositions for delivery are included
as are different methods of delivery such as placing the microorganisms in food.
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ORAL ADMINISTRATION OF 
COPROSTANOL PRODUCING 
MICROORGANISMS TO HUMANS TO 
DECREASE PLASMA CHOLESTEROL 
CONCENTRATION 
CROSS REFERENCE TO RELATED 
APPLICATION 
This is a continuation of application Ser. No. 07/970,565 
?led on Nov. 3, 1992 noW abandoned and a continuation 
in-part of commonly assigned application Ser. No. 07/796, 
403 ?led Nov. 22, 1991 now US. Pat. No. 5,436,004, Which 
is itself a continuation-in-part of Ser. No. 07/339,229, ?led 
Apr. 17, 1989 noW abandoned, Which is itself a continuation 
in-part of Ser. No. 07/222,016 ?led Jul. 21, 1988, now US. 
Pat. No. 4,921,710, issued May 1, 1990. 
BACKGROUND OF THE INVENTION 
Coronary heart disease, atherosclerosis, is the leading 
cause of human mortality in the United States, as Well as in 
many other developed countries, and is responsible for more 
deaths than all forms of cancer combined. It is generally 
recogniZed that high blood cholesterol concentrations pro 
vide a signi?cant risk factor associated With atherosclerosis. 
Cholesterol is present in the blood as free and esteri?ed 
cholesterol Within lipoprotein particles, commonly knoWn as 
chylomicrons, very loW density lipoproteins, loW density 
lipoproteins and high density lipoproteins. Concentration of 
total cholesterol in the blood is in?uenced by (1) absorption 
of cholesterol from the digestive tract, (2) synthesis of 
cholesterol from dietary constituents such as carbohydrates, 
proteins, fats and ethanol, and (3) removal of cholesterol 
from blood by tissues, especially the liver, and subsequent 
conversion of the cholesterol to bile acids, steroid hormones, 
and biliary cholesterol. The bile acids and cholesterol in bile 
are secreted into the intestine from Which they may be 
recycled back to the blood or be excreted into the feces. In 
summation of these physiological processes, the concentra 
tion of cholesterol in the blood is controlled by a balance of 
inputs and outputs. The tWo inputs are cholesterol absorbed 
from the diet and cholesterol that is synthesiZed Within the 
body and secreted into the blood. Typical values of adult 
humans for absorption are 335 mg daily and for synthesis are 
800 mg. 
The outputs regulating the concentration of cholesterol in 
blood include sloughing skin cells (about 85 mg cholesterol 
daily), excretion of steroid hormones (about 50 mg choles 
terol daily), excretion of bile acids in feces (400 mg cho 
lesterol equivalent daily), and excretion of sterols in feces 
(600 mg cholesterol equivalent daily). The fecal sterols 
include cholesterol, cholestanol, coprostanol, and plant ste 
rols. The Whole body of the adult human contains about 100 
grams of cholesterol, most of Which is in the nonester?ed 
form. 
Maintenance of blood cholesterol concentrations is in?u 
enced by both genetic and environmental factors. Genetic 
factors include concentration of rate-limiting enZymes in 
cholesterol biosynthesis, concentration of receptors for loW 
density lipoproteins in the liver, concentration of rate 
limiting enZymes for conversion of cholesterols bile acids, 
rates of synthesis and secretion of lipoproteins and gender of 
person. Environmental factors in?uencing the hemostasis of 
blood cholesterol concentration in humans include dietary 
composition, incidence of smoking, physical activity, and 
use of a variety of pharmaceutical agents. Dietary variables 
include amount and type of fat (saturated and polyunsatu 
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2 
rated fatty acids), amount of cholesterol, amount and type of 
?ber, and perhaps amounts of vitamins such as vitamin C 
and D and minerals such as calcium. 
Pharmaceutical agents in current use that usually cause a 
hypocholesterolemic response include lovastatin, Which 
decreases cholesterol synthesis in the body, and 
cholestyramine, Which increases bile acid excretion. An 
increase in bile acid excretion causes the liver of the person 
to convert more cholesterol to bile acids and to incorporate 
less cholesterol in very loW density and loW density lipo 
proteins for secretion into the blood. Hence, cholestyramine 
usually causes a hypocholesterolemic response. 
Similar to that for bile acid excretion, increases in the 
excretion of cholesterol and other sterols into the feces 
usually Will cause a hypocholesterolemic response because 
the liver Would partition more cholesterol into the bile and 
thus less Would be available for incorporation into lipopro 
teins for secretion into the blood. Typically, a human 
secretes about 1,000 mg of cholesterol from the liver into the 
bile for entry into the small intestine. This biliary cholesterol 
then becomes a part of the dietary cholesterol pool in the 
small intestine and thus may be absorbed to maintain 
cholesterol homeostasis. 
The present invention discloses a method and means for 
decreasing the amount of biliary and dietary cholesterol that 
is absorbed by the small intestine through oral administra 
tion of coprostanol-producing microorganisms. Several spe 
cies of bacteria including Eubacterium coprostanoligenes 
(previously called Eubacterium sp. strain HL by us) isolated 
in pure culture from an IoWa State University hog lagoon 
(ATCC No. 21408) contain the enZyme cholesterol reduc 
tase. These bacteria, Which produce this enZyme, are capable 
of converting cholesterol to coprostanol. The resultant 
coprostanol product is absorbed poorly by humans and, 
instead of being absorbed through the intestine into the 
blood, Will be passed through the intestine and excreted in 
the feces of the human. 
Thus, an objective of the present invention is to decrease 
cholesterol absorption in the small intestine through admin 
istration of coprostanol-producing microorganisms. 
Another object of the invention is to convert cholesterol 
present in the small intestine to coprostanol, Which Will be 
excreted. 
Yet another objective of the invention is to loWer plasma 
concentration of cholesterol in humans by generating a 
hypocholesterolemic response resulting in partitioning by 
the liver of more cholesterol into bile With less available for 
incorporation into lipoproteins for secretion into the blood. 
Another objective of the present invention is to provide a 
pharmaceutical composition for oral administration, Which 
Will release the coprostanol-producing organisms in the 
small intestine of humans. 
The method and means of accomplishing each of the 
above objectives as Well as others Will become apparent 
from the detailed description of the invention that folloWs 
hereinafter. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph shoWing a decrease in plasma choles 
terol concentration for rabbits treated With orally adminis 
tered Eubacterium coprostanoligenes. 
SUMMARY OF THE INVENTION 
This invention relates to the oral administration of 
coprostanol-producing microorganisms as a means of 
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decreasing cholesterol concentrations in the blood of 
humans. These microorganisms Will decrease blood choles 
terol concentrations by converting biliary and dietary 
cholesterol, Which normally Would be absorbed through the 
small intestine, to nonabsorbable coprostanol, Which then is 
excreted. The invention also comprises a pharmaceutical 
composition for administration of the microorganisms. Pref 
erably the microorganisms are encapsulated in a dose deliv 
ery system that decreases the probability of release of the 
organisms in the human stomach but increases the probabil 
ity of release in the proximal small intestine. The microor 
ganisms also may be administered as a constituent of foods, 
such as milk, meats, and yogurt. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Eubacterium coprostanoligenes has been deposited at the 
American Type Culture Collection, 10801 University Bou 
levard Manassas, Va. 20110-2209, USA on Feb. 10, 1993. 
The deposit strain has been assigned Accession No. 51,222. 
The culture deposited With the AT CC is taken from the same 
cultures maintained by IoWa State University, Department of 
Animal Science, Ames, IoWa 50011, since prior to the ?ling 
date of this application. This culture at IoWa State University 
has been maintained under conditions Which assure access to 
the cultures Will be available during the pendency of this 
patent application to those determined by the Commissioner 
of Patents and Trademarks to be entitled thereto under 37 
C.F.R. § 1.14 and 35 USC § 122. 
The deposits are available as required by foreign patent 
laWs in countries Wherein counterparts of the subject appli 
cation or its progeny, are ?led. HoWever, it should be 
understood that applicant granting of permission to the 
depository to distribute samples of the deposit does not 
constitute an expressed or implied license to practice the 
invention claimed in any patent issuing on the subject 
application or any other patent. 
The subject cultured deposits Will be stored and made 
available to the public in accordance With the provisions of 
the Budapest Treaty for the deposit of microorganisms, i.e., 
they Will be stored With all the care necessary to keep them 
viable and uncontaminated for a period of at least ?ve years 
after the most recent request for the furnishing of a sample 
of the deposits, and in any case, for a period of at least thirty 
(30) years after the date of deposit or for the enforcable life 
of any patent Which may issue disclosing the cultures. The 
depositor acknoWledges the duty to replace the deposit 
should the depository be unable to furnish a sample When 
requested, due to the condition of the deposits. All restric 
tions on the availability to the public of the subject culture 
deposits Will be irrevocably removed upon the granting of a 
patent disclosing them. 
The mechanism of the enZyme cholesterol reductase and 
its presence in Eubacterium coprostanoligenes species and 
in several green plants has already been Well described and 
documented in several of my earlier patent applications, of 
Which this is a continuation in part. US. Pat. No. 4,921,710 
comprises a method of converting cholesterol in food to 
coprostanol by addition of cholesterol reductase to foods and 
by injection of the enZyme prior to slaughter for meat 
animals. In addition, there is a continuation-in-part applica 
tion noW in prosecution for oral administration of the 
cholesterol reductase enZyme to humans to reduce endog 
enous and dietary cholesterol. There is also noW a pending 
application that proposes to insert the cholesterol reductase 
producing gene sequence into meat-producing animals so 
that it can be “turned on” to decrease cholesterol concen 
trations. These applications and patents are all incorporated 
herein by reference. 
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As described in earlier applications, coprostanol, Which is 
absorbed poorly by humans, is the product representing 
cholesterol that has been hydrogenated. This reaction is 
enhanced by the enZymatic activity of cholesterol reductase. 
This enZyme is present in Eubacterium coprostanoligenes 
isolated from a hog lagoon at IoWa State University. Several 
other Eubacteria, such as Eubacterium coprostanoligenes 
ATCC 21408, also contain the ability to produce the enZyme 
and thereby reduce cholesterol to coprostanol. The present 
application represents yet another extension in clinical and 
industrial use of cholesterol reductase and involves direct 
ingestion of the bacteria that contain cholesterol reductase 
into the small intestine of the humans, alloWing the micro 
organism to convert cholesterol present in the small intestine 
to coprostanol, Which is then excreted rather than absorbed. 
The human digestive tract receives dietary cholesterol and 
liver-derived endogenous cholesterol via secretion of bile 
into the upper part of the small intestine. In addition, cells 
sloughed from the digestive tract contribute cholesterol that 
becomes available for absorption into the intestinal mucosal 
cells. Typically, diet (about 700 mg per day), sloughed cells 
(about 400 mg per day), and bile (about 1000 mg per day) 
contribute more than 2000 mg of cholesterol daily for 
absorption. The majority of this cholesterol is present as free 
cholesterol because that is the major form of cholesterol in 
food, slough cells and bile. Pancreatic cholesterol esterase 
Will catalyZe conversion of any cholesteryl esters in the 
intestinal lumen to free cholesterol and free fatty acids. 
Enrichment of contents of the small intestine With one or 
more species of coprostanol-producing bacteria Will cause 
conversion of cholesterol in the intestinal contents to 
coprostanol, Which is absorbed poorly. Some of the bacteria 
may become attached to the intestinal mucosal cells and thus 
carry coprostanol synthesis at or near the site of cholesterol 
absorption. The enrichment of the small intestinal contents, 
especially the upper part Where signi?cant cholesterol 
absorption occurs, Will decrease markedly the ef?ciency of 
absorption of both dietary and endogenous cholesterol, and 
thus the liver of the human recipient Will partition a greater 
percentage of its cholesterol toWard the small intestine via 
the bile and less toWard the blood. This partitioning change 
Will occur because less biliary and dietary cholesterol is 
transferred to the liver due to cholesterol conversion to the 
coprostanol in the intestinal lumen. 
Pharmaceutical compositions for the introduction of these 
coprostanol-producing bacteria into the small intestine 
include bacteria that have been lyophilyZed or froZen in 
liquid or paste form and encapsulated in a gel capsule. The 
gel cap material must be a speci?c polymeric material to 
form a delivery pill or capsule that is resistant to degradation 
by the gastric acidity and pepsin of the stomach but is 
degraded With concomitant release of bacteria by the higher 
pH and bile acid contents in the proximal small intestine. 
The released and noW active bacteria then Would catalyZe 
conversion of cholesterol present in the small intestine to 
coprostanol. Pharmaceutical carriers also could be combined 
With the bacteria. These Would include saline-phosphate 
buffer for a solution that may be directly administered to the 
person. 
Another method of administration of these microorgan 
isms to the small intestine Would include adding the 
coprostanol-producing bacteria directly to food sources. 
Foods, such as yogurt or milk, may be supplemented With 
coprostanol-producing organisms Without affecting their 
taste or appearance. Upon ingestion, When the food products 
are being digested and absorbed by the small intestine, the 
microorganisms Will convert cholesterol present in the small 
intestine to coprostanol, preventing absorption of the cho 
lesterol into the blood stream. 
EXAMPLE 1 
The ability of orally administered coprostanol-producing 
bacteria to decrease serum blood cholesterol concentrations 
is demonstrated by the folloWing example. 
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SiX adult NeW Zealand White rabbits Were assigned 
randomly to tWo groups of three rabbits each. Treated rabbits 
received 4 ml of Eubacterium coprostanoligenes suspension 
(72x107 cells/ml). Control rabbits received the same dose of 
a boiled (dead) Eubacterium coprostanoligenes. The strain 
of bacteria that We used Was a coprostanol-producing 
Eubacterium coprostanoligenes sp. that Was isolated in pure 
culture from an IoWa State University hog lagoon. Eubac 
terium sp. strain HL (hog lagoon), noW called Eubacterium 
coprostanoligenes, is described in a doctoral dissertation 
Written by Timothy A. Freier during 1991 and is available in 
the IoWa State University Library. The bacterial preparations 
Were administered via a tube placed into the esophagus once 
daily for 10 days beginning on day 50 and concluding on day 
59. On day 1 of the experimental period, cholesterol Was 
added to the diet at a concentration of 0.05% of air-dry 
Weight of the feed to cause hypercholes-terolemia. On day 
38, the cholesterol concentration of the diet Was increased to 
0.10%. This diet Was fed to the rabbits through day 94. 
The effects of oral administration of the Eubacterium 
coprostanoligenes suspension on plasma cholesterol con 
centrations are shoWn in FIG. 1. The plasma cholesterol 
concentration Was elevated from about 75 mg % to about 
225 mg % by the supplemental dietary cholesterol. The 
effect of bacteria Was not observed until after 8 days of 
administration of the bacteria, but the hypocholesterolemic 
effect Was still observed 33 days after the rabbits Were no 
longer fed the bacteria. From day 64 through day 94, plasma 
cholesterol concentration of treated rabbits (189 mg %) Was 
signi?cantly loWer (P<0.001) than that of controls (276 mg 
%). When intestinal contents of control and treated rabbits 
Were assayed for the presence of Eubacteria, the treated 
rabbits had maintained signi?cantly greater numbers of the 
coprostanol-producing bacteria in the contents of the cecum 
and large intestine. Maintenance of Eubacterium copros 
tanoligenes in the treated rabbits occurred because of (1) 
attachment of Eubacterium coprostanoligenes to the intes 
tinal and cecal epithelia and/or (2) recycling of the Eubac 
terium coprostanoligenes through the digestive tract via 
coprophagy. The treated rabbits had signi?cantly greater 
amount of coprostanol in their fecal samples than did the 
control rabbits. Furthermore, administration of the Eubac 
terium coprostanoligenes had no adverse effects on consis 
tency of the feces or on health of the rabbits. 
In conclusion, these data clearly indicate that oral admin 
istration of a coprostanol-producing bacterium caused sig 
ni?cant hypocholesterolemic effects in rabbits. Similar 
effects Would be eXpected in humans because of the many 
similarities in nutrition, physiology, and biochemistry of 
rabbits and humans. 
EXAMPLE 2 
Prophetic 
Foods that are about to be ingested could be supplemented 
With coprostanol-producing microorganisms. Coprostanol 
producing Eubacterium coprostanoligenes Would be groWn 
in media and separated from the media in a paste form by 
centrifugation. Traditional yogurt cultures obtained from 
any commercial dairy could be miXed With the Eubacterium 
coprostanoligenes culture. This miXture of cultures then 
could be added to the basic dairy yogurt premiX Without 
affecting taste or consistency. The yogurt then Would be 
produced and packaged by using traditional commercial 
procedures. In another example, the Eubacterium copros 
tanoligenes could be added to already produced yogurts. 
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Another eXample Would be to add the Eubacterium 
coprostanoligenes to milk after it has been homogeniZed and 
steriliZed. Such a method is currently used for adding the 
Lactobacillus acidophilus organisms to milk by the dairy 
industry. These commercial procedures likely could be used 
With coprostanol-producing Eubacterium With similar 
results. Any food source containing bacteria could likely be 
used by supplementing With coprostanol producing bacteria, 
such as cheese or meat products that have selected micro 
organisms added during processing. 
Once these food products have been prepared to contain 
the coprostanol-producing organisms, they may be ingested. 
Once in the small intestine, the Eubacterium coprostanoli 
genes Will perform the familiar reduction of cholesterol to 
coprostanol. 
What is claimed is: 
1. Amethod of decreasing blood cholesterol concentration 
in hypercholesterolemic mammals, said method comprising: 
(a) orally administering cholesterol reducing effective 
amount of Eubacterium coprostonaligenes microor 
ganism into the small intestine of said mammal. 
2. The method of claim 1 Wherein said mammal is a 
human. 
3. The method of claim 1 Wherein absorption of dietary 
and endogenous cholesterol is decreased due to reduction of 
cholesterol to coprostanol by said microorganism. 
4. The method of claim 3 Wherein said coprostanol is not 
absorbed by the small intestine but is instead eXpelled in the 
feces of said mammal. 
5. A pharmaceutical composition for use in reduction of 
blood cholesterol concentration in humans, said composition 
comprising: 
Eubacterium coprostanoligenes microorganism having 
ATCC Accession No. 51,222 and a pharmaceutically 
acceptable carrier. 
6. The pharmaceutical composition of claim 5 Wherein 
said microorganism is in a cholesterol-reducing effective 
unit dosage form. 
7. The pharmaceutical composition of claim 5 Wherein 
said pharmaceutically acceptable carrier is saline-phosphate 
buffer solution. 
8. The pharmaceutical composition of claim 5 Wherein 
said pharmaceutical carrier is a material useful for introduc 
ing said composition that is medically acceptable and does 
not interfere With the cholesterol-reducing properties of said 
microorganism. 
9. The composition of claim 5 Wherein said composition 
is encapsulated in a pill or capsule that is resistant to 
degradation by gastric acidity and pepsin, but is degraded 
With concomitant release of said Eubacterium coprostano 
ligenes microorganism by higher pH and bile acids present 
in the proXimal small intestine. 
10. The composition of claim 9 Wherein said Eubacterium 
coprostanoligenes microorganisms are freeZe dried. 
11. A method of decreasing blood cholesterol concentra 
tion in rabbits, said method comprising: 
(a) orally administering a cholesterol reducing effective 
amount of Eubacterium coprostanoligenes into the 
small intestine of a rabbit; 
(b) decreasing absorption of dietary and endogenous 
cholesterol, through conversion of said cholesterol to 
coprostanol by said microorganism. 
